Multiomics-based risk prediction tool for early identification of AIH patients

Background and Aims: Autoimmune hepatitis (AIH) is a chronic liver disease characterised by an autoimmune response against hepatocytes. Early diagnosis is crucial in preventing disease progression. However, it remains challenging due to the limited availability of appropriate diagnostics, such as liver biopsy. In this study, we aim to develop a risk prediction tool based on widely available biomarkers to identify patients-at-risk populations, that could benefit from a more elaborated or AIH-focused diagnostic approach.